Showing papers in "European Journal of Cancer in 2018"

TL;DR: The present estimates of the cancer burden in Europe alongside a description of the profiles of common cancers at the national and regional level provide a basis for establishing priorities for cancer control actions across Europe.

TL;DR: In this phase 2 trial, cabozantinib treatment significantly prolonged PFS per IRC compared with sunitinib as initial systemic therapy for advanced RCC of poor or intermediate risk.

TL;DR: A monocentric retrospective analysis of consecutive advanced NSCLC patients treated with an anti-programmed cell death-1 or anti- program death-ligand 1.1 found that patients with PsPD or dissociated response had higher overall survival than patients with true progression.

TL;DR: In patients treated with anti-PD-1 antibody, pre-existing AID was associated with a significantly increased risk of irAEs, and results indicate that cancer treatments withAnti- PD-1 antibodies are just as effective in AID patients as they are in AIDs-free patients.

TL;DR: The OS of MBC patients has slightly improved over the past decade, however, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.

TL;DR: Low cumulative doses of anthracyclines in adult patients with low cardiovascular risk can raise troponins, without differences between the two strategies of giving enalapril.

TL;DR: Long-term DFS and PFS were similar between groups and patients who achieved tpCR had improved DFS; no new safety signals were identified.

TL;DR: Trends in incidence for in situ and invasive melanoma in some European countries during the period 1995-2012 were analysed, stratifying for lesion thickness, with a statistically significant increase in invasive lesions.

TL;DR: Veliparib was well tolerated, but no confirmed response was observed although four patients remained on study with SD for ≥ 4 months, and ongoing trials are evaluating PARPis combined with chemotherapy and as a maintenance strategy.

TL;DR: It is demonstrated that cfDNA is a surrogate marker of tumour burden in metastatic melanoma patients, and that it is prognostic for overall survival.

TL;DR: Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment, and quality assured and quality controlled imaging data included in databases will establish a large and high-quality imaging warehouse for future research.

TL;DR: Reappraisals of Swedish mammography trials demonstrate that the design and statistical analysis of these trials were different from those of all trials on screening for cancers other than breast cancer, and compelling indications that these trials overestimated reductions in breast cancer mortality associated with screening are found.

TL;DR: It is found that routine mammography screening is not feasible in Ghana at the moment which therefore requires a different approach to improve breast cancer care in Ghana.

TL;DR: Patients with HIV or hepatitis B/C infections treated with anti-PD-1/PD-L1 immunotherapy may respond to treatment without increased toxicity, given the risk of graft rejection in solid organ transplant patients and also the potential for response.

TL;DR: Beyond response assessment, medical imaging can detect irAE and guide towards specific management and described the most frequent sites and patterns of imaging findings.

TL;DR: The data show the high medical need for efficient and tolerable antitumour therapies and demonstrate that despite older age and comorbidities, most patients can be expected to be fit for treatment.

TL;DR: Despite intensified treatment and staging procedures, long-term survival for women with EOC has not improved in the last 25 years, and the observed improvements in 5-year OS reflect a more prolonged disease control rather than better chances for cure.

TL;DR: The latest discoveries for harnessing blood-based biomarkers as novel BC screening tools are summarized, as well as the limitations and challenges that need to be overcome before the translation of their use from the bench to the bedside are discussed.

TL;DR: The EORTC Cutaneous Lymphoma Task Force Committee have reviewed the literature and held a Workshop (June 2017) to agree a definition of blood-class according to flow cytometry, and propose absolute counts of either CD4+CD7-or CD4 + CD26-where B0<250/μL, B1 = 250/ μl-<1000/μl and B2≥1000/ μL plus a T-cell blood clone.

TL;DR: Several countries showed increases in MCC incidence among white non-Hispanics over time, and Latitude closer to the equator was associated with the Mcc incidence in North American men, but barely in women, possibly due to occupational sunlight exposure patterns.

TL;DR: These EAP results suggest that elderly patients with advanced squamous NSCLC benefit from nivolumab, with tolerability similar to that in the overall population.

TL;DR: Findings support pembrolizumab monotherapy as standard of care in patients with advanced melanoma, regardless of first- or second-line therapy or PD-L1 status.

TL;DR: Ultrasound detected more BCs but caused more false positives than tomosynthesis, underscoring trade-offs in screening outcomes when adjunct imaging is used for screening dense breasts.

TL;DR: Using a multiplex testing approach, 28% of CUP carried one or more predictive biomarkers (MSI-H, PD-L1 and/or TML-H) to the immune checkpoint blockade, providing a novel option for treatment in patients with CUP.

TL;DR: PD-L1 and the maximum standardised uptake value (SUVmax) were identified as independent prognostic predictors by multivariate analysis and could be a significant marker for predicting worse outcomes in AC patients with high 18F-FDG uptake but not in those with low18F- FDG uptake.

TL;DR: The presence of FOXP3-positive TILs is a potential prognostic marker for stage I-III SCLCs and warrants further investigation and may differ according to stage.

TL;DR: In this large international cohort of patients treated with first-line immunochemotherapy, outcomes following SCNS remain poor, however, a moderate proportion of patients with isolated SCNS who received intensive therapies achieved durable remissions.

TL;DR: The FIRE-3 trial findings illustrate the potential for conversion to resectability in mCRC, certain reluctance towards metastatic resections in clinical practice and the need for pre-planned and continuous evaluation for metastatics resection in high-volume centres.

TL;DR: Consumption of processed meat, but not red meat, may increase the risk of breast cancer.

TL;DR: Findings from this first-in-human phase I study demonstrate that IMAB362 is generally well tolerated and support further evaluation in patients with gastric/gastro-oesophageal junction cancer.